Patents by Inventor TEJASHREE JOGLEKAR

TEJASHREE JOGLEKAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10842785
    Abstract: The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: November 24, 2020
    Assignee: THE UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventors: Charles J. Bieberich, Xiang Li, Tejashree Joglekar
  • Publication number: 20200046689
    Abstract: The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 13, 2020
    Inventors: CHARLES J. BIEBERICH, XIANG LI, TEJASHREE JOGLEKAR
  • Patent number: 10525047
    Abstract: The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: January 7, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventors: Charles J. Bieberich, Xiang Li, Tejashree Joglekar
  • Publication number: 20190076416
    Abstract: The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.
    Type: Application
    Filed: March 22, 2017
    Publication date: March 14, 2019
    Inventors: CHARLES J. BIEBERICH, XIANG LI, TEJASHREE JOGLEKAR